RPS6KB1 and malignant colon neoplasm: Taken together, our results demonstrate that Everolimus treatment disrupts the S6K1-IRS-2/PI3K negative feedback in colon cancer cells and leads to BRAF600E-dependent activation of EKR and Mcl-1 stabilization.